Verrica Pharmaceuticals (NASDAQ:VRCA) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Verrica Pharmaceuticals (NASDAQ:VRCA) from a sell rating to a hold rating in a research note released on Thursday morning.

Several other equities research analysts also recently weighed in on the company. Needham & Company LLC reissued a “hold” rating on shares of Verrica Pharmaceuticals in a report on Wednesday, May 14th. HC Wainwright reissued a “neutral” rating on shares of Verrica Pharmaceuticals in a report on Tuesday, April 8th. Five analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, Verrica Pharmaceuticals has a consensus rating of “Hold” and an average price target of $8.00.

Verrica Pharmaceuticals Stock Down 2.7%

NASDAQ VRCA opened at $0.62 on Thursday. Verrica Pharmaceuticals has a twelve month low of $0.38 and a twelve month high of $9.36. The company has a market cap of $57.34 million, a price-to-earnings ratio of -0.34 and a beta of 1.73. The business’s fifty day moving average is $0.51 and its 200 day moving average is $0.68.

Verrica Pharmaceuticals (NASDAQ:VRCA) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.04. Verrica Pharmaceuticals had a negative return on equity of 591.84% and a negative net margin of 625.06%. The company had revenue of $3.44 million for the quarter, compared to the consensus estimate of $2.53 million. On average, research analysts anticipate that Verrica Pharmaceuticals will post -1.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Barclays PLC lifted its holdings in Verrica Pharmaceuticals by 404.6% during the 3rd quarter. Barclays PLC now owns 31,341 shares of the company’s stock worth $45,000 after buying an additional 25,130 shares during the period. Invesco Ltd. acquired a new position in Verrica Pharmaceuticals during the 4th quarter worth about $32,000. AQR Capital Management LLC lifted its holdings in Verrica Pharmaceuticals by 306.7% during the 1st quarter. AQR Capital Management LLC now owns 58,711 shares of the company’s stock worth $26,000 after buying an additional 44,275 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Verrica Pharmaceuticals by 127.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 99,505 shares of the company’s stock worth $44,000 after buying an additional 55,852 shares during the period. Finally, Kovitz Investment Group Partners LLC bought a new position in shares of Verrica Pharmaceuticals in the 1st quarter worth about $45,000. 42.45% of the stock is owned by institutional investors and hedge funds.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.